Lannett to distribute generic Adderall
Lannett has entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of Teva’s Adderal (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate). The company will distribute the generic in dosage strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg.
Adderall is a central nervous system stimulant, indicated for the treatment of attention deficit hyperactivity disorder and Narcolepsy.
"We expect to launch this generic version of Adderall near term," Lannett CEO Tim Crew said. "We look forward to expanding this relationship and launching more products over time. We believe Elite and SunGen selected Lannett as the distributor of the product because of our team's ability to launch products swiftly and execute launch plans well."
Adderall, including generic versions had a market value of roughly $361 million for the 12 months ended January 2019, although actual generic market values are expected to be lower.
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.
Adderall is a central nervous system stimulant, indicated for the treatment of attention deficit hyperactivity disorder and Narcolepsy.
"We expect to launch this generic version of Adderall near term," Lannett CEO Tim Crew said. "We look forward to expanding this relationship and launching more products over time. We believe Elite and SunGen selected Lannett as the distributor of the product because of our team's ability to launch products swiftly and execute launch plans well."
Adderall, including generic versions had a market value of roughly $361 million for the 12 months ended January 2019, although actual generic market values are expected to be lower.
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.